CD44 and neoplasm: In light of our observations that CD44 augments heregulin sensitivity, we suggest that the presence of CD44 on breast tumour cells in clinical tissue may further aid identification of tumours less likely to respond to conventional therapy, an effect likely to be exacerbated in instances where tumour CD44 and stromal heregulins are co-expressed.